Substantial Increase in Costs With Metastases in Prostate CA

This article originally appeared here.
Share this content:
Substantial Increase in Costs With Metastases in Prostate CA
Substantial Increase in Costs With Metastases in Prostate CA

FRIDAY, June 2, 2017 (HealthDay News) -- Diagnosis of subsequent metastases is associated with substantially increased costs and medical resource use (MRU) among patients initially diagnosed with localized prostate cancer (PC), according to a study published online May 23 in Cancer.

Tracy T. Li, Ph.D., from Janssen Global Services in Raritan, N.J., and colleagues identified 7,482 patients diagnosed with metastases 12 months or more after diagnosis of localized PC, and 25,709 localized PC patients without subsequent metastases (controls). Patients were followed for costs and MRU from 12 months before the index date.

The researchers found that predicted monthly costs remained relatively stable throughout the observation period among the controls (weighted mean per patient per month, $2,746). Among cases there was an increase in costs from $2,622 at 12 months before diagnosis of subsequent metastases to $4,767 at one month before diagnosis of subsequent metastases; costs peaked at $13,291 during the month of metastasis diagnosis, and remained significantly higher thereafter ($4,677 at 12 months after metastases diagnosis). There were increases in costs and MRU across a wide range of settings and types.

"In PC patients initially diagnosed with localized disease, a diagnosis of subsequent metastases is associated with substantially increased costs and MRU," the authors write.

Several authors disclosed financial ties to pharmaceutical and health care companies, including Janssen Global Services, which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »